Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development. (22nd February 2011)

• Record Type: Journal Article
• Authors: Broen, J C A; Gourh, P; Vonk, M C; Beretta, L; Niederer, F; Rueda, B; Geurts-van Bon, L; Brouwer, C; Hesselstrand, R; Herrick, A; Worthington, J; Hunzelman, N; Fonseca, Denton C; Riemekasten, G; Kiener, H; Scorza, R; Simeon, C P; Fonollosa, V; Carreira, P; Ortego-Centeno, N; Gonzalez-Gay, M A; Airo', P; Coenen, M J H; Mayes, M; Kyburz, D; Arnett, F C; Martin, J; Radstake, T R D J
• Is Part Of: Annals of the rheumatic diseases. Volume 70(2011)Supplement 2
• Page Start: A19
• Page End: A19
• Publication Date: 2011-02-22
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2010.148965.15
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Aim: Pre-B cell colony-enhancing factor (PBEF) is intricately involved in inflammation and fibrosis, functional polymorphisms of PBEF have been previously shown to influence PBEF expression and pulmonary damage. Systemic sclerosis (SSc) is a disease in which inflammation, fibrosis and pulmonary deterioration are prominent hallmarks. Therefore the authors here investigate the role of the PBEF -1001T>G and PBEF -1543C>T polymorphisms in the genetic predisposition to SSc susceptibility and pulmonary involvement. Patients and methods: The authors genotyped DNA from 2737 SSc patients and 1913 matched healthy controls, both from eight different ethnic populations. Genotyping was performed using custom Taqman 5' allelic discrimination assays. In addition, PBEF serum expression levels were measured by ELISA and correlated with genotypes. Results: In two separate populations and in a meta-analysis, the combined PBEF -1543CC -1001TT genotype, hence carrying no minor alleles, was found associated with SSc susceptibility (p=0.009 OR 1.20 (95% CI 1.05 to 1.37)). In addition, these subjects showed an increased decline in forced vital capacity over 15 years follow-up (p=0.02) (HR 1.64, 95% CI 1.02 to 2.64) and a higher PBEF serum concentration (p<0.01), compared to carriers of minor alleles. On the other hand, patients with genotype PBEF -1001TT were at lower risk for PAH development within 15 years of disease onset compared to the carriers with genotypes PBEF -1001GG and PBEF -1001TG (p<0.001) (HR 3.29, 95% CI 1.52 to 7.12). Conclusions: This data identify PBEF as a novel candidate gene that influences SSc susceptibility, pulmonary function and the development of PAH.